#oncology-startups

#oncology-startups

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, confirming its commitment to advancing healthcare and life sciences.

The funds raised through Visionaries of the Year are used for research to advance lifesaving therapies like immunotherapy, genomics and personalized medicine, which are saving lives today.

The Stanley Family Foundation announced another $280 million for the Stanley Center for Psychiatric Research at Broad Institute earlier this month, bringing its total contributions to the Massachusetts-based nonprofit over $1 billion.

Nicolas Sauvage, president of TDK Ventures, will explain the unique operations of corporate VCs and what founders should know about attracting investment.

When mitochondria are exposed to tissue or blood, they lose the electrical gradient across their outer membrane. Mitochondria that lack such a gradient are recognized by a cell's internal machinery as damaged and quickly destroyed. The vast majority of previous studies involved injecting 'naked' mitochondria directly into the bloodstream or tissue sites, but the approach isn't very efficient, so researchers often have to use 'ridiculous' doses of mitochondria.

X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.

The company on February 11 announced it had raised $100 million in Series C funding as it pursues FDA approval of LOY-002, a beef-flavored daily prescription pill designed to extend the healthy lifespan of senior dogs. The drug mimics some of the effects of a calorie-restricted diet in addressing age-related metabolic issues without requiring pet owners to cut their dogs' food supply or curbing canine appetites.

But he'd been considering an idea for new technology-an autonomous, wind-powered cargo ship. Then, while on paternity leave in 2024, he discovered a free program that helps scientists and engineers launch businesses for the first time. Weeks after finishing the program, called 5050, Cymbalist had launched a startup called Clippership. The company's first ship is being built in the Netherlands this year. Without the accelerator, he says, the company likely wouldn't exist.

We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.

I'm certainly confident that we're going to have a breakthrough within my career, and I have a good 10 to 15 years left. While antiretroviral (ARV) therapies are extending lives and keeping HIV at bay, and PrEP has the potential to effectively halt transmission of the virus, a cure has remained elusive. That's because the HIV virus itself is elusive, both co-opting the immune system and hiding from it.

Anais Muczynski, 36, an orthoptist who lives with her husband Vincent Muczynski, 41, a researcher, received her primary breast cancer diagnosis in January 2023 after discovering a quail egg-sized lump in her left breast. At the time, the London-based couple were "optimistic", as it was stage one meaning the cancer was only in the breast tissue or in the lymph nodes close to the breast and she underwent chemotherapy, immunotherapy, and a double mastectomy.

Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.

But these studies typically require large numbers of patients, huge amounts of data, and thorough follow-ups, none of which comes easy or free. The upshot is fewer investigations into scenarios that are clinically important but unlikely to yield a profit for the firms funding them. Accordingly, researchers have been developing an option that uses real-world data from insurers to save patients from falling through the cracks.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,